Minocycline “may be a good choice” for infections caused by Stenotrophomonas maltophilia, “an inherently resistant organism with limited treatment options,” concluded authors of a retrospective study presented at IDWeek.
Use of protease inhibitors was associated with higher rates of liver aminotransferase elevations in patients with HIV; however, severe acute liver injury was uncommon with all antiretroviral therapy (ART) regimens, concluded a retrospective cohort study presented at IDWeek 2016.
Overall sustained virologic response (SVR) rate for ledipasvir/sofosbuvir in hepatitis C virus (HCV)/HIV co-infected patients in real world settings was 95.2%.
Relebactam (MK-7655) restored imipenem activity against many respiratory tract infection isolates from the US and Canada, researchers reported at IDWeek 2016.
For patients with hepatitis C virus (HCV) infection genotype (GT) 1-6, treatment with sofosbuvir/velpatasvir plus voxilaprevir (GS-9857) once daily was safe, well tolerated, and highly effective in treatment-naive and treatment-experienced patients, reported Ronald Nahass, MD, FIDSA, FSHEA, from ID Care, Inc., Hillsborough, NJ, at IDWeek 2016.
An age- and gender-based pooled analysis presented at IDWeek 2016 showed that delafloxacin had comparable outcomes to vancomycin at 48-72 hours for the treatment of acute bacterial skin and skin structure infections (ABSSSI).
The investigational anti-HIV integrase inhibitor cabotegravir (CAB) is well-tolerated, according to a meta-analysis of clinical trial data reported at IDWeek 2016.
Trimethoprim-sulfamethoxazole (TMP-SMX) or clindamycin treatment following small abscess incision and drainage (I&D) improves outcomes.
A total of 2,538 patients taking piperacillin/tazobactam and 1,134 patients taking levofloxacin were included in the analysis.
GSK’s investigational combined measles, mumps, and rubella (MMR) vaccine (GSK_MMR) “demonstrated an acceptable immune response” that was non-inferior to Merck’s MMR vaccine (MRK_MMR), a multinational, randomized, Phase 3A, controlled, observer-blinded study reported at IDWeek 2016 has shown.
